IRVINE, Calif., Sept. 23 /PRNewswire-FirstCall/ -- Endocare, Inc.
(Nasdaq: ENDO), an innovative medical device company focused on the
development of minimally invasive technologies for tissue and tumor
ablation, announced today that the American Urological Association (AUA)
has for the first time posted on its website the organization's official
"best practice" document on cryoablation for prostate cancer, covering
primary, salvage and focal cryoablation, also called cryosurgery. The AUA
posting of these clinical guidelines is an acknowledgement of the important
advances made in the technology of cryoablation, a minimally invasive
treatment for prostate cancer that freezes cancerous tumors to destroy
them, said Endocare Chairman, President and CEO Craig T. Davenport.

"This is a principled and unbiased assessment of the effectiveness of
cryoablation for treating prostate cancer made by the country's most
prestigious association of urologists," Davenport said. "The AUA panel that
did the assessment looked at all the published studies of cryoablation and
came to the conclusion that it is a valuable treatment that should be
considered by prostate cancer patients. The publication of these guidelines
helps to place cryoablation more squarely in the mainstream of prostate
cancer treatments."

The 51-page document, titled "Best Practice Policy Statement on
Cryosurgery for the Treatment of Localized Prostate Cancer" and officially
adopted at the recent AUA national conference, specifically notes the
"seven-to-eight-year biochemical disease free results of cryosurgery. The
literature reports that the morbidity profile associated with cryosurgery
has improved in all aspects, including continence, rectal/urethral fistula
formation, urethral sloughing, and potency in association with the
technological advances over the last 10 to 15 years."

About Endocare

Endocare, Inc. -- http://www.endocare.com -- is an innovative medical
device company focused on the development of minimally invasive
technologies for tissue and tumor ablation. Endocare has initially
concentrated on developing technologies for the treatment of prostate
cancer and believes that its proprietary technologies have broad
applications across a number of markets, including the ablation of tumors
in the kidney, lung and liver and palliative intervention (treatment of
pain associated with metastases).

(Date:10/5/2017)... ... 2017 , ... LabRoots , the leading provider of educational and interactive ... back to cancer research with a month-long promotion supporting the advancement of breast cancer ... can use promo code PinkRibbon to get 10 percent off their purchase of every ...

(Date:10/5/2017)... ... October 05, 2017 , ... NIH ... of its Nanobind DNA/RNA extraction technology . Nanobind is a novel magnetic ... surface and that can be used for a wide variety of sample preparation ...

(Date:3/30/2017)... March 30, 2017 On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...

(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...

(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...